Síntesis y reparación de ADN Crecimiento y división celular
S- ACETIL-GLUTATIÓN REDUCIDO
7.14 ESTRATEGIA PARA NORMALIZAR EL GLUTATIÓN CELULAR
La literatura médica reporta que frenar el declive de los niveles de glutatión podría causar efectos benéficos en los pacientes con diversos desórdenes
relacionados con deficiencia de GSH.49 La dosis
oral del éster de GSH (S-acetil glutatión), es de 100 mg cada 12 horas y se puede duplicar esta dosis en caso de deficiencia severa. La duración de la suplementación debe ser de mínimo 3 meses. Es recomendable determinar niveles de GSH en sangre total en los pacientes con alta probabilidad de desarrollo de enfermedades neurodegenerativas o relaciona- das con el envejecimiento para iniciar un tratamiento temprano y continuo, y así retrasar las complicacio- nes que suelen ser causadas por estrés oxidativo.61 7.15 CONTRAINDICACIONES Y ADVERTENCIAS
No hay casos reportados de toxicidad por suplemen- tación de glutatión en la literatura médica. La única advertencia reportada a la fecha es con respecto al uso concomitante de GSH con quimioterapia, ya que las células cancerígenas pueden utilizar el GSH para resistir ante agentes quimioterapéuticos.69
Tabla 3. Patología de órganos asociados con niveles reducidos de Glutatión.57
Cardiovascular
Endocrino
Gastrointestinal
Hígado
Músculo esquelético
Neurológico
Pulmones
Riñones
Vesícula biliar
Tabla 4. Condiciones específicas asociadas con niveles reducidos de Glutatión.
Autismo58 Esquizofrenia59
Cataratas60 Fibrosis cística 66
Diabetes62 Gastritis 45
Enfermedad de Alzheimer 57 Hepatitis C 63
Enfermedad Coronaria39 Hiperlipidemia64
Enfermedad de Crohn46 Síndrome de dificultad
respiratoria aguda65
Enfermedad de Parkinson51 Síntomas asociados
con toxicidad ambiental (Metales pesados y
xenobióticos)56,66
REFERENCIAS
1. Sen CK. Nutritional biochemistry of cellular glutathione. Nutr Biochem 1997;8:660-672.
2. Cook GC, Sherlock S. Results of a controlled clinical trial of glu- tathione in cases of hepatic cirrhosis. Gut 1965;6:472-476. 3. Kidd PM. Glutathione: systemic protectant against oxidative and
free radical damage. Altern Med Rev 1997;1:155-176. 4. Bremer HJ, Duran M, Kamerling JP, et al. Glutathione. In:
Disturbances of Amino Acid Metabolism:Clinical Chemistry and Diagnosis. Baltimore-Munich: Urban and Schwarzenberg; 1981:80-82. 5. Cai J, Nelson KC, Wu M, et al. Oxidative damage and protection of
the RPE. Progr Retinal Eye Res 2000;19:205-221.
6. Look MP, Rockstroh JK, Rao GS, et al. Serum selenium, plasma glutathione (GSH) and erythrocyte glutathione peroxidase (GSH- Px)-levels in asymptomatic versus symptomatic human immunode- ficiency virus-1 (HIV-1)-infection. Eur J Clin Nutr 1997;51:266-272. 7. Luo J-L, Hammarqvist F, Andersson K, et al. Surgical trauma
decreases glutathione synthetic capacity in human skeletal muscle tissue. Am J Physiol 1998;275:E359-E365.
8. Spies CD, Reinhart K, Witt I, et al. Influence of N-acetylcysteine on direct indicators of tissue oxygenation in septic shock patients: results from a prospective, randomized, double-blind study. Crit Care Med 1994;22:1738-1746.
9. Whitcomb DC, Block GD. Association of acetaminophen hepatotoxi- city with fasting and ethanol use. JAMA 1994;272:1845- 1850. 10. Castrejón Sosa M (2007) Radicales libres y sistemas antioxidantes.
En: Bioquímica: un enfoque básico aplicado a las ciencias de la vida. Editores: Diaz-Zagoya JC, Juárez- Oropeza MA. McGraw-Hill Interamericana, México. pp 611-628.
11. Halliwell B (2006) Oxidative stress and neurodegeneration: where are we now? J Neurochem 97:1634-1658.
12. Anderson ME. Glutathione and glutathione delivery compounds. Adv Pharmacol 1997;38:65-78
13. Verjee ZH, Behal R. Protein-calorie malnutrition: a study of red blood cell and serum enzymes during and after crisis. Clin Chim Acta 1976;70:139-147.
14. Weber GF. Final common pathways in neurodegenerative diseases: regulatory role of the glutathione cycle. Neurosci Biobehav Rev 1999;23:1079-1086.
15. Gravina P et al. Genetic polymorphisms of glutathione
Stransferases GSTM1, GSTT1, GSTP1 and GSTA1 as risk factors for schizophrenia. Psychiatry Res 2011 187:454-456.
16. Van Lieshout EM1, Peters WH. Age and gender dependent levels of glutathione and glutathione S-transferases in human lymphocytes. Carcinogenesis. 1998 Oct;19(10):1873-5.
17. Julius M, Lang CA, Glieberman L, et al. Glutathione and morbi- dity in a community- based sample of elderly. J Clin Epidemiol 1994;47:1021-1026.
18. Strange RC, Jones PW, Fryer AA. Glutathione S-transferase: gene- tics and role in toxicology. Toxicol Letts 2000;112-113:357-363. 19. Ballatori N et al. Glutathione dysregulation and the etiology and
progression of human diseases. Biol Chem (2009) 390:191-214. 20. Franco R, Cidlowski JA, Apoptosis and glutathione: beyond an
antioxidant. Cell Death Differ (2009) 16:1303-1314.
21. Lindahl T, Wood RD. Quality control by DNA repair. Science. 1999 Dec 3;286(5446):1897-905.
22. Rajesh M et al. Accumulation of 8-hydroxydeoxy- guanosine and its relationship with antioxidant parameters in patients with
Eales’ disease: implications for antioxidant therapy. Curr Eye Res.
2003;27(2):103-110.
23. Lenton KJ et al. Glutathione and ascorbate are negatively correlated with oxidative DNA damage in human lymphocytes. Carcinogenesis. 1999;20(4):607-613.
24. Allameh A et al. Role of glutathione conjugation in protection of weanling rat liver against acetaminophen-induced hepatotoxicity. Mech Ageing Dev. 1997;95(1-2):71-79.
25. Witschi A et al Eur J Clin Pharmacol. The systemic availability of oral glutathione. 1992;43(6):667-9.
26. John P. Richie Jr. et al. Randomized controlled trial of oral glu- tathione supplementation on body stores of glutathione. Eur J Nutr published online May 5, 2014
27. Jacobson GA, et al. Selenoprotein P analysis in human plasma: a discrepancy between HPLC fractionation of human plasma with heparin-affinity chromatography and SDS-PAGE with immunoblot analysis. Biol Trace Elem Res. 2005;107(3):213-220.
28. Brown KM, Arthur JR. Selenium, selenoproteins and human health: a review. Public Health Nutr. 2001;4(2B):593-599.
29. Swanson CA, Patterson BH and al. Human [74Se]selenomethionine metabolism: a kinetic model. Am J Clin Nutr. 1991 Nov;54(5):917-26 30. Abdulah R, Miyazaki K, Nakazawa M, et al. Chemical forms of
selenium for cancer prevention. J Trace Elem Med Biol. 2005;19(2- 3):141-150.
31. El-Sayed WM, Aboul-Fadl T, Lamb JG, et al. Effect of selenium- containing compounds on hepatic chemoprotective enzymes in
mice. Toxicology. 2006;220(2-3):179-188.
32. McCormick, D.B. 1996. Co-enzymes, Biochemistry of. In: Encyclopedia of Molecular Biology and Molecular Medicine, Vol. 1. Meyers, R.A., ed. Weinheim: VCH, p. 396-406.
33. Adelekan DA, Thurnham DI. Glutathione peroxidase (EC 1.11.1.9) and superoxide dismutase (EC 1.15.1.1) activities in riboflavin- deficient rats infected with Plasmodium berghei malaria. Br J Nutr.
1998;79:305-309.
34. Warsy AS1, el-Hazmi MA. East Mediterr Health J. Glutathione reductase deficiency in Saudi Arabia.1999 Nov;5(6):1208-12. 35. Lee DH, Gross MD et al. Is serum gamma-glutamyltransfe-
rase a biomarker of xenobiotics, which are conjugated by glutathione?Arterioscler Thromb Vasc Biol. 2008 Apr;28(4):e26-8. 36. Gul M, Kutay FZ, Temocin S, et al. Cellular and clinical implications
of glutathione. Indian J Exp Biol 2000;38:625-634.
37. Usal A, Acarturk E, Yuregir GT, et al. Decreased glutathione levels in acute myocardial infarction. Jpn Heart J 1996;37:177- 182. 38. Amano J, Suzuki A, Sunamori M. Salutary effect of reduced glu-
tathione on renal function in coronary artery bypass operation. J Am
Coll Surg 1994;179:714-720.
39. Prasad A, Andrews NP, Padder FA, et al. Glutathione reverses endothelial dysfunction and improves nitric oxide bioavailability. J
Am Coll Cardiol 1999;34:507-514.
40. Meister A, Larsson A. Glutathione synthetase deficiency and other disorders of the gamma-glutamyl cycle. In: Scriver CR, Kinzler KW, Valle D, et al, eds. The Metabolic and Molecular Bases of Inherited Diseases. New York: McGraw-Hill; 1995:1461-1477.
41. Loguercio C, Taranto D, Vitale LM, et al. Effect of liver cirrhosis and age on the glutathione concentration in the plasma, erythrocytes,
and gastric mucosa of man. Free Rad Biol Med 1996;20:483-488.
42. Altomare E, Vendemiale G, Alano O. Hepatic glutathione content in patients with alcoholic and non alcoholic liver diseases. Life Sci 1998;43:991-998.
43. Heard KJ. Acetylcysteine for acetaminophen poisoning, N Engl J Med. 2008 Jul 17;359(3):285-92.
44. Suter PM, Domenighetti G, Schaller MD, et al. N-acetylcysteine enhances recovery from acute lung injury in man. Chest
1994;105:190-194.
45. Park DK et al. Glutathione levels in Helicobacter pylori-infected gastric mucosa. Korean J Gastroenterol. 2003 Oct;42(4):267-73. 46. Iantomasi T, Marraccini P, Favilli F, et al. Glutathione metabolism in
Crohn’s disease. Biochem Med Metab Biol 1994;53:87- 91.
47. Pace GW, Leaf CD. The role of oxidative stress in HIV disease. Free Rad Biol Med 1995;19:523-528.
48. Halliwell B (2006) Oxidative stress and neurodegeneration: where are we now? J Neurochem 97:1634-1658.
49. Jesús Martínez-Sámano et al. El glutation y su asociación con las enfermedades neurodegenerativas, la esquizofrenia, el envejeci- miento y la isquemia cerebral, REB 30 (2): 56-67, 2011
50. Dringen R et al. Glutathione metabolism in brain, metabolic inte- raction between astrocytes and neurons in the defense against reactive oxygen species.Eur J Biochem 2000 267: 4912-4916. 51. Martin HL, Teismann P Glutathione: a review on its role and signifi-
cance in Parkinson´s disease. FASEB J 2009 23:3263-3272. 52. Bain JS, Shaw CA Neurodegenerative disorders in humans: the role
of glutathione in oxidative stress-mediated neuronal death. Brain Res Rev 1997 25:335-358.
53. Ghosh N, Ghosh R, Mandal SC Antioxidant protection: A promising therapeutic intervention in neurodegenerative disease. Free Radic Res 2011 DOI: 10.3109/10715762.2011.574290.
54. Raffa M et al. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2009 33: 1178–1183. 55. Micó JA, Rojas-Corrales MO et al. Reduced antioxidant defense
in early onset first-episode psychosis: a case control study. BMC Psychiatry 2011 11:26.
56. Patrick L. Mercury toxicity and antioxidants: Part 1: role of glutathio- ne and alpha-lipoic acid in the treatment of mercury toxicity. Altern Med Rev. 2002 Dec;7(6):456-71.
57. Lang CA, Mills BJ, Mastropaolo W, Liu MC. Blood glutathio- ne decreases in chronic diseases. J Lab Clin Med. May 2000;135(5):402-405.
58. Yorbik O, Sayal A, Akay C, Akbiyik DI, Sohmen T. Investigation of antioxidant enzymes in children with autistic disorder. Prostaglandis Leukot Essent Fatty Acids. Nov 2002;67(5):341-343.
59. Steullet P, Neijt HC, Cuenod M, Do KQ. Synaptic plasticity impair- ment and hypofunction of NMDA receptors induced by glutathione deficit: Relevance to schizophrenia. Neuroscience. Dec 1 2005. 60. Truscott RJ. Age-related nuclear cataract-oxidation is the key. Exp
Eye Res. May 2005;80(5):709-725.
61. Surendran S, Rajasankar S Parkinson´s disease: oxidative stress and therapeutic approaches. Neurol Sci 2010 31:531-540. 62. Forrester TE, Badaloo V, Bennett FI, Jackson AA. Excessive excre-
tion of 5-oxoproline and decreased levels of blood glutathione in
type II diabetes mellitus. Eur J Clin Nutr. 1990;44(11):847-850.
63. Salem TA, El-Refaei MF, Badra GA. Study of antioxidant enzymes level and phagocytic activity in chronic liver disease patients. Egypt
J Immunol. 2003;10(1):37-45.
64. Pemberton PW, Smith A, Warnes TW. Non-invasive monitoring of oxidant stress in alcoholic liver disease. Scand J Gastroenterol. Sep
2005;40(9):1102- 1108.
65. Bernard GR, Wheeler AP, Arons MM, et al. A trial of antioxidants N- acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS
Study Group. Chest. Jul 1997;112(1):164-172.
66. Harris C, Dixon M, Hansen JM. Glutathione depletion modulates methanol, formaldehyde and formate toxicity in cultured rat concep- tuses. Cell Biol Toxicol. May 2004;20(3):133-145.
67. Kaviarasan K, Arjunan MM, Pugalendi KV. Lipid profile, oxidant- antioxidant status and glycoprotein components in hyperlipidemic patients with/ without diabetes. Clin Chim Acta. Dec 2005;362(1- 2):49-56.
68. Sbrana E, Paladini A, Bramanti E, Spinetti MC, Raspi G. Quantitation of reduced glutathione and cysteine in human immunodeficiency virus- infected patients. Electrophoresis. Jun
2004;25(10-11):1522-1529.
69. Mulder GJ, Ouwerkerk-Mahadevan S. Modulation of glutathione conjugation in vivo: how to decrease glutathione conjugation in vivo or in intact cellular systems in vitro. Chem-Biol Interact 1997;105:17- 34.
70. Rossini Giuseppe, University of Milan,Italy, pendiente de publica- ción.
Regeneración del Epitelio Intestinal